Drugs / IM-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07250750 | Feb 2026 → Dec 2027 expected | myasthenia gravis | ImmunAbs Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IM-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07250750 ↗ |
| Route | Intravenous | “IM-101 intravenously (IV)” NCT07250750 ↗ |